Equities analysts forecast that Vical Incorporated (NASDAQ:VICL) will post earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Vical’s earnings, with estimates ranging from ($0.20) to ($0.16). Vical posted earnings of ($0.29) per share in the same quarter last year, which indicates a positive year over year growth rate of 37.9%. The business is expected to report its next earnings report on Thursday, May 2nd.
According to Zacks, analysts expect that Vical will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.34). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Vical.
Vical (NASDAQ:VICL) last announced its earnings results on Tuesday, February 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.04 million. Vical had a negative return on equity of 33.58% and a negative net margin of 1,002.10%.
Hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Vical during the first quarter valued at $146,000. JPMorgan Chase & Co. grew its holdings in shares of Vical by 47.5% during the third quarter. JPMorgan Chase & Co. now owns 138,960 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 44,723 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Vical by 10.1% during the third quarter. Renaissance Technologies LLC now owns 966,549 shares of the biotechnology company’s stock valued at $1,324,000 after buying an additional 88,820 shares in the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.
Shares of Vical stock traded up $0.01 on Friday, reaching $1.16. 51,658 shares of the company were exchanged, compared to its average volume of 146,505. The firm has a market capitalization of $25.31 million, a PE ratio of -1.43 and a beta of 0.56. Vical has a fifty-two week low of $0.85 and a fifty-two week high of $1.82.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Featured Story: How to read a candlestick chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.